Oric Pharmaceuticals (ORIC)
(Delayed Data from NSDQ)
$8.60 USD
-0.23 (-2.60%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $8.58 -0.02 (-0.23%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Oric Pharmaceuticals, Inc. [ORIC]
Reports for Purchase
Showing records 21 - 40 ( 56 total )
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ORIC-114 Inserting Into the EGFR/HER2 Landscape
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Late Breaking Abstract Round Up for ESMO 2023
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ESMO 2023 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Initiating coverage with an OUTPERFORM rating and a $14 price target
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The ORICle Predicts Overcoming Resistance; Initiating at OUTPERFORM, $14 PT
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Several Datasets in Coming Quarters; 2Q23 Financials; Modulating PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Competitive Landscape Updates From ASCO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Clinical Readouts in 2H23; 1Q23 Financials; Modulating PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Correction: Multiple Clinical Readouts in 2H23; 1Q23 Financials; Modulating PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Adding Pipeline Programs to Our Valuation; Upgrading to Buy and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ORIC-101 Halted; FY2021 Financials; Downgrading to Neutral, Removing PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ORIC-114''s Clinical Trial Application Cleared by Korean Regulatory Authorities; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Key Upcoming Milestones Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R